-
MU
Micron Technology
-
#1
-
AAPL
Apple
-
#2
-
NVDA
NVIDIA
-
#3
-
PLTR
Palantir Technologies
-
#4
-
SPCX
Space Exploration Technologies Corp.
-
#5
-
SNDK
Sandisk Corporation
-
#6
-
AVGO
Broadcom
-
#7
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Strength in Medical & Fluid Solutions Unit Drives Nordson: Can It Sustain?
by Zacks Equity Research
NDSN is gaining momentum as its Medical and Fluid Solutions segment delivers solid organic growth and margin expansion.
Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?
by Zacks Equity Research
DHR sees Biotechnology core revenues rise 6.5% in Q3 2025, fueled by bioprocessing demand, with approximately 5% growth expected in Q4.
InnovAge (INNV) Moves 7.8% Higher: Will This Strength Last?
by Zacks Equity Research
InnovAge (INNV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SOLV vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
SOLV vs. DHR: Which Stock Is the Better Value Option?
SOLV or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SOLV vs. DHR: Which Stock Is the Better Value Option?
Unlocking Danaher (DHR) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Explore Danaher's (DHR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Company News for Oct 22, 2025
by Zacks Equity Research
Companies in The News Are: KO, DHR, RTX, VST
Danaher Q3 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR Q3 earnings and sales beat estimates, driven by solid segment growth and stronger operating margins.